Isoniazid prophylaxis for tuberculosis in HIV infection: A meta-analysis of randomized controlled trials

AIDS

Volumn 13, Issue 4, 1999, Pages 501-507

  Bucher, Heiner C ^a   Griffith, Lauren E ^b   Guyatt, Gordon H ^b   Sudre, Philippe ^c   Naef, Marcel ^a   Sendi, Pedram ^a   Battegay, Manuel ^a  

^a KANTONSSPITAL BASEL   (Switzerland)

^b MCMASTER UNIVERSITY   (Canada)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

AIDS; AIDS related opportunistic infections; HIV infections; Isoniazid; Meta analysis; Mycobacterium tuberculosis; Primary prevention

Indexed keywords

ISONIAZID; TUBERCULOSTATIC AGENT;

AIDS RELATED COMPLEX; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; HUMAN; INCIDENCE; META ANALYSIS; MORTALITY; RANDOMIZED CONTROLLED TRIAL; TUBERCULOSIS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTITUBERCULAR AGENTS; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; ISONIAZID; META-ANALYSIS; TUBERCULOSIS;

EID: 0033545450     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199903110-00009     Document Type: Article

References (35)

1. Narain JP, Raviglione MC, Kochi A: HIV-associated tuberculosis in developing countries: epidemiology and strategies for prevention. Tuber Lung Dis 1992, 73:311-321.
2. Chaisson RE, Schecter GF, Theuer CP, Rutherford GW, Echenberg DF, Hopewell PC: Tuberculosis in patients with the acquired immunodeficiency syndrome. Am Rev Respir Dis 1987, 136:570-574.
3. Perriens JH, Colebunders RL, Karahunga C, et al.: Increased mortality and tuberculosis treatment failure rate among human immunodeficiency virus (HIV) seropositive compared with HIV seronegative patients with pulmonary tuberculosis treated with 'standard' chemotherapy in Kinshasa, Zaire. Am Rev Respir Dis 1991, 144:750-755.
4. Nunn P, Brindle R, Carpentier L, et al.; Cohort study of human immunodeficiency virus infection in patients with tuberculosis in Nairobi, Kenya. Am Rev Respir Dis 1992, 146:849-854.
5. Perneger TV, Sudre P, Lundgren JD, Hirschel B: Does the onset of tuberculosis in AIDS predict shorter survival? Results of a cohort study in 17 European countries over 13 years. BMJ 1995, 311:1468-1471.
6. Ferebee SH; Controlled chemoprophylaxis trials in tuberculosis: a general review. Adv Tuberc Res 1970, 17:28-106.
7. Selwyn PA, Hartel D, Lewis VA: A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989, 320:545-550.
8. Gulear A, Gatell JM, Verdejo J: A prospective study of the risk of tuberculosis among HIV-infected patients. AIDS 1993, 7:1345-1349.
9. Guelar A, Gatell JM, Verdejo J, et al.: A prospective study of the risk of tuberculosis among HIV-infected patients. AIDS 1993, 7:1345-1349.
10. Moreno S, Baraia-Etxaburu J, Bouza E, et al.; Risk for developing tuberculosis among anergic patients infected with HIV. Ann Intern Med 1993, 119:194-198.
11. Graham NMH, Galai N, Nelson KE, et al.: Effect of isoniazid chemoprophylaxis on HIV-related mycobacterial disease. Arch Intern Med 1996, 156:889-894.
12. Gordin FM, Matts JP, Miller C, et al.: A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. N Engl J Med 1997, 337:315-320.
13. Whalen CC, Johnson JL, Okwera A, et al.: A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. N Engl J Med 1997, 337:801-808.
14. Hawken MP, Meme HK, Elliott LC. et al.: Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: results of a randomized controlled trial. AIDS 1997, 11:875-882.
15. Jadad AR, Moore RA, Jenkinson C, Reynolds DJ, Gavagahn DJ: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996, 17:1-12.
16. Mwinga A, Godfrey-Faussett P, Quigley M, et al.: Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS 1998 (in press).
17. Pape JW, Jean SS, Ho JL, Hafner A, Johnson WD Jr: Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 1993, 342:268-272.
18. American Thoracic Society/Medical Section of the American Lung Association: Diagnostic standards and classification of tuberculosis. Am Rev Respir Dis 1990, 142:725-735.
19. Valdespino JL, Garcia ML, Daniels E, et al.: Outcomes of the pilot study of TB chemoprophylaxis trials. IX International Conference on AIDS. Berlin, June 1993 [abstract PO-BO7-114].
20. Wadhawan D, Hira S, Mwansa N, Sunkulu R, Adera T, Perine P: Preventive tuberculosis chemotherapy with isoniazid among patients infected with HIV-1. XI International Conference on AIDS. Berlin, June 1993 [abstract PO-BO7-1133].
21. Der Simonian R, Laird N: Meta-analysis in clinical trials. Contr Clin Trials 1986, 7:177-188.
22. Rothman KJ: Modern Epidemiology. Boston: Little, Brown and Company; 1986.
23. Greenland S: Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 1987, 9:1-30.
24. Halsey NA, Coberly JS, Desormeaux J, et al.: Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet 1998, 351:786-792.
25. Matteelli A, Carosi G, Signorini L, Tebaldi A, Caligaris S, Gulletta M: Multinational study for the preventive therapy of latent tuberculosis in HIV positive individuals: isoniazid versus rifabutin. 12th World AIDS Conference. Geneva, June July 1998 [abstract 60858].
26. Wilkinson D, Squire SB, Garner P: Effect of tuberculosis preventive therapy in adults infected with HIV: systematic review of randomised placebo controlled trials. BMJ 1998, 317:625-629.
27. Oxman AD, Guyatt GH: A consumer's guide to subgroup analyses. Ann Intern Med 1992, 116:78-84.
28. Schulz KF, Chalmers I, Grimes DA, Altmnan DG: Assessing the quality of randomization from reports of controlled trials published in obstetrics and gynecology, JAMA 1994, 272:125-128.
29. Jaeschke R, Guyatt GH, Shannon H, Walter SD, Cook DJ, Heddle N: Basic statistics for clinicians. III. Assessing the effects of treatment: measures of association. Can Med Assoc J 1995, 152:351-357.
30. Selwyn PA, Sckell BM, Alcabes P, Friedland GH, Klein RS, Schoenhaum FE: High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy. JAMA 1992, 268:504-509.
31. Melnick SI, Sherer R, Louis TA, et al.: Survival and disease progression according to gender of patients with HIV infection. JAMA 1994, 272:1915-1921.
32. Dupon M, Texier-Maugein J, Leroy V, et al.: Tuberculosis and HIV infection: a cohort study of incidence and susceptibility to antituberculous drugs, Bordeaux, 1985-1993. AIDS 1995, 9:577-583.
33. Markowitz N, Hansen NI, Hopewell PC, et al.: Incidence of tuberculosis in the United States among HIV-infected persons. Ann Intern Med 1997, 126:123-132.
34. Aisu T, Raviglione MC, van Praag E, et al.: Preventive chemotherapy for HIV-associated tuberculosis in Uganda: an operational assessment at a voluntary counselling and testing center. AIDS 1995, 9:267-272.
35. Ngamvithayapong J, Uthaivoravit W, Yanai H, Akarasewi P, Sawanpanyalert P: Adherence to tuberculosis preventive therapy among HIV infected persons in Chiang Rai, Thailand, AIDS 1997, 11:107-112.